Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Neil declares war on greedy drugs makers

Post Thumbnail

Health Secretary Alex Neil has called for an end to overpriced cancer drugs and pledged the NHS is going to get tough with greedy pharmaceutical firms.

The SNP minister said the body which advises health boards on whether to buy new medicines is going take a harder line in negotiations over their price.

The call was echoed by the former chairman of Scottish Medicines Consortium who accused the big drugs companies of a “your money or your life” approach to introducing new cancer drugs.

The Sunday Post’s “Fighting Chance” campaign is pressing for big improvements to cancer patient care across the country and many of those sufferers are losing out on new drugs which can ease their pain simply because the medicines cost too much.

Mr Neil, addressing a fringe event at the SNP conference in Perth, also called for a pan-European solution to fight back against the high prices charged by drug firms.

He said: “If the pharmaceutical companies keep over-pricing or trying to rig the price I’m not accusing the industry of that but there are some players who give that impression then quite frankly they will not only do damage to the health of the nation but they also do a lot of damage to their own prospects.

“If we had a EU-wide policy in relation to pricing of orphan drugs for example and we spoke with one EU voice and negotiated with drug companies on an EU basis, that would give us the kind of negotiating strength we think is needed to get a fairer deal.

On the SMC’s role in approving new drugs, he added: “Rather than just say no, I would like us to be much more robust in going back to the companies and saying ‘look, if you would reduce the price to more around this figure instead of that figure the chances are we will approve it’.

Our campaign has revealed how cancer patients who have been referred to hospital are facing a postcode lottery over delays to starting treatment, with increasing numbers waiting more than three months.

Some cancers appear to be being given a lower priority than others with health board finances often dictating whether patients will get cancer drugs and live any longer.

Mr Neil’s concern over drug prices was supported by former SMC chairman Professor Ken Paterson.

He said: “This is not a new problem. Ten years ago an expensive medicine cost £5,000 to £10,000, today an expensive medicine is coming in at £50,000 to £100,000 a tenfold increase.

“There’s no competition, it’s a little bit like a highwayman approach, your money or your life. You either pay this or we keep the drug.

“As a health service we need to take a harder line with pharma firms and say we are not prepared to be held to ransom, we are not prepared to pay over the odds for these medicines.

“Make them feel some of the pain that we are feeling as a health service.”

Lesley Stephen, 48, a mother of four from Edinburgh diagnosed with secondary breast cancer in March, told the Breakthrough Breast Cancer event of the personal toll of being denied lifesaving cancer drugs.

She said: “The shock of being told, out of the blue, you have incurable cancer is indescribable.When my consultant told me about [cancer drug] Kadcyla I felt very optimistic, as did he. I thought I would be a good candidate and it could extend my life by number of months if not years and still allow me a quality of life with my children.

“There is not a lot of hope living with metastatic cancer and you are constantly praying that new treatments will come about before it is too late for you personally and Kadcyla gave me that hope.

“When I heard it had been rejected by the SMC, I was very angry I felt a price had been put on my life but that my life was not worth that price.”